Abstract
In an update from the phase III PENELOPE‐B trial, palbociclib did not improve invasive disease‐free survival when added to endocrine therapy in patients with HR‐positive, HER2‐negative breast cancer who were considered to be at high risk for recurrence following neoadjuvant chemotherapy.